Assessing the Mechanisms and Impact of a Novel Cannabinoid Product for Gynecologic Pain

Recruiting Phase 1 Phase 2 Interventional Study
Endometriosis Adenomyosis Chronic Pelvic Inflammatory Disease
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
21 and older
Sex
Female
Trial phase
Phase 1/2
Study type
Interventional
Purpose
Treatment
Participants needed
60 (estimated)
Sponsor
Staci Gruber, Ph.D. · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Despite recent increases in both medical and recreational cannabis use in the United States and globally, little research has been conducted to determine the potential applications for womens health. A variety of medical cannabis and hemp-derived products on the marketplace claim to hold efficacy for many womens health-related conditions, including gynecologic pain. This 7-day study of individuals…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Provides informed consent * Sex assigned female at birth * Capable of having menstrual cycles * Aged 21+ * Endorses one of the following gynecologic pain conditions: endometriosis, adenomyosis, chronic pelvic inflammatory disease (PID) * Stable medication/psychotherapy regimen…
Contacts

Staci Gruber, PhD

617-855-2762

gruber@mclean.harvard.edu

CONTACT

Rosie Smith, M.S.

617-855-2908

rsmith@mclean.harvard.edu

CONTACT